AMPA Receptors

Antagonists


Cat.No.	Product Name / Activity
1082	CFM-2
	Non-competitive AMPA antagonist
0190	CNQX
	Potent AMPA/kainate antagonist
1045	CNQX disodium salt
	Potent AMPA/kainate antagonist. More water soluble form of CNQX (Cat. No. 0190)
2932	CP 465022 hydrochloride
	Selective, non-competitive AMPA antagonist
0189	DNQX
	Selective non-NMDA antagonist
2312	DNQX disodium salt
	Selective non-NMDA antagonist. Water-soluble salt of DNQX (Cat. No. 0189)
0845	Evans Blue tetrasodium salt
	AMPA/kainate antagonist
3099	GYKI 47261 dihydrochloride
	Non-competitive AMPA antagonist
1454	GYKI 52466 dihydrochloride
	Selective non-competitive AMPA antagonist
2555	GYKI 53655 hydrochloride
	Non-competitive AMPA receptor antagonist
4198	IEM 1925 dihydrobromide
	Voltage- and use-dependent open-channel antagonist of AMPA receptors
2766	Naspm trihydrochloride
	Ca²⁺-permeable AMPA receptor antagonist
0373	NBQX
	Potent AMPA antagonist. More selective than CNQX (Cat. No. 0190)
1044	NBQX disodium salt
	Potent AMPA antagonist. More water soluble form of NBQX (Cat. No. 0373)
2770	Philanthotoxin 74
	GluR1/2 selective AMPA antagonist
0961	SYM 2206
	Non-competitive AMPA antagonist
1765	UBP 282
	AMPA/kainate antagonist; distinguishes between motoneuron and dorsal root kainate receptors
2701	YM 90K hydrochloride
	Selective AMPA antagonist
2345	ZK 200775
	Competitive AMPA/kainate antagonist

View all AMPA Receptor products

Quick Order

Find multiple products by catalog number

Pain Research Guide

Reserve your free copy

Highlights over 280 products for Pain research. Reserve copy

Calcium Imbalance and Neuroprotective Targets

Written by E. Besancon et al

'Calcium Imbalance and Neuro-protective Targets in Cerebral Ischemia & Brain Injury' highlights the key targets involved in stroke, trauma and neurodegeneration.

Neurobiology of Parkinson's Disease

Written by A. Schapira

'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.

Antidepressants - Current and Future Targets

Written by P. Skolnich et al

'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.

Therapeutic Strategies in Schizophrenia

Written by J. Lieberman

'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.